Author

Stuart Madden

Institution: Neurelis (United States)

Observed institution: Neurelis (United States)

ORCID: 0009-0000-8039-131X

Observed ORCID: 0009-0000-8039-131X

OpenAlex ID: A5103092087

Optimizing Absorption for Intranasal Delivery of Drugs Targeting the Central Nervous System Using Alkylsaccharide Permeation Enhancers

2023 · Stuart Madden, Enrique Carrazana, et al. · Pharmaceutics · 41

Alternative Approaches for Addressing Acute Agitation in Schizophrenia and Bipolar Disorder

2024 · Leslie Citrome, Christoph U. Correll, et al. · The Primary Care Companion For CNS Disorders · 5

Safety, Tolerability, and Pharmacokinetics of NRL-1049, a Rho-Associated Kinase Inhibitor, in Healthy Volunteers: A Phase 1, First-in-Human, Single-Ascending Dose, Randomized, Placebo-Controlled Trial

2025 · Stuart Madden, Issam Awad, et al. · CNS Drugs · 4

A Single-Dose, Randomized, Open-Label, Parallel Design Study to Characterize the Pharmacokinetics of an Investigational Olanzapine Intranasal Spray Compared to a Reference Dose of Olanzapine Intramuscular Injection in Healthy Adult Males

2025 · Stuart Madden, Leslie Citrome, et al. · The Journal of Clinical Psychiatry · 2

Evaluating Bioequivalence of a New, Higher-Concentration Diazepam Nasal Spray for Seizure Clusters Compared with the Current Formulation in Healthy Adults

2026 · Stuart Madden, Miguel A. Lopez-Toledano, et al. · Neurology and Therapy

Clinical insights: an update on transmucosal absorption with a focus on dodecyl maltoside

2026 · Adrian L. Rabinowicz, Stuart Madden, et al. · Expert Opinion on Drug Delivery

Works count: 6

Citation count: 52

H-index: 3

I10-index: 1